Oruka Therapeutics, Inc. (ORKA)
Oruka Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Menlo Park, CA, US. The stock last traded at $84.46, down 1.20% on the session, giving a market capitalisation of $5.09B. On trailing twelve-month figures it carries a trailing P/E of -34.19, a net margin of 0.0%. Its beta of -0.39 implies it has historically moved less than the broad market.
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Oruka Therapeutics, Inc. is most often compared with the following Healthcare names: